Skip to main content
      RT @Janetbirdope: Case control study to see if MTX is assoc with ILD in RA. Hypersensitivity pneumonitis pts were exclud

      Janet Pope Janetbirdope

      4 years 6 months ago
      Case control study to see if MTX is assoc with ILD in RA. Hypersensitivity pneumonitis pts were excluded. MTX use assoc with DELAYED onset of ILD so protective. let my RA pts use MTX if ILD or increased ILD risk ex male old +RF OP0036 @RheumNow @eular_org @CRASCRRheum #EULAR2020 https://t.co/NGM4t2OKTP
      RT @pkiely500: #EULAR2020 OP0026. RITAZAREM. Rituximab superior to Aza 2mg/kg in maintaining remission in relapsing AAV.

      Patrick Kiely pkiely500

      4 years 6 months ago
      #EULAR2020 OP0026. RITAZAREM. Rituximab superior to Aza 2mg/kg in maintaining remission in relapsing AAV. Flare rate 13% vs 38%. Note Ritux schedule is 1g every 4 months (x 5 infusions out to month 20).
      RT @Janetbirdope: Can we treat GPA /ANCA vasculitis without steroids? Apparently yes +RCT by P Merkel in #EULAR2020 plen

      Janet Pope Janetbirdope

      4 years 6 months ago
      Can we treat GPA /ANCA vasculitis without steroids? Apparently yes +RCT by P Merkel in #EULAR2020 plenary adding avacopan-blocks C5a. Gutsy move as No steroids in one arm! ?cost effectiveness but a breakthrough @RheumNow @eular_org @CRASCRRheum https://t.co/kp7IZOaHfP
      This week's Tuesday Nite Rheumatology featured Dr Jonathan Kay (U Mass) who gave an update on Biosimilars and took questions the subject. The program was moderated by Dr. Jack Cush.
      Faith
      For Jessica, an ICU nurse, 12-hour shifts were usually fast paced, challenging and productive. But the cadence and demands of work abruptly changed mid-March when COVID-19 came. Amongst her many ICU admissions she took care of Larry, who was instantly interesting and forever memorable. He had contracted the coronavirus less than a week before. He was a 60-ish yr. old man who tried to be humorous, but who was clearly distressed and worried. He
      RT @KDAO2011: Dr. R Landewe highlights #EULAR2020 #COVID19 Guidelines:
      1. RMD-patients do NOT have higher risk for compl

      k dao KDAO2011

      4 years 6 months ago
      Dr. R Landewe highlights #EULAR2020 #COVID19 Guidelines: 1. RMD-patients do NOT have higher risk for complications 2. Rheumatologists SHOULD BE involved in management discussions 3. Potential shortages of sDMARDS and biologics @rheumnow https://t.co/sjQubD7mJL
      RT @pompermarioMD: Patients with RA-ILD vs RA only: More likely to be older, male, white and RF positive. More likely to

      Mario Pompermayer, MD pompermarioMD

      4 years 6 months ago
      Patients with RA-ILD vs RA only: More likely to be older, male, white and RF positive. More likely to have COPD, Rheumatoid nodules, erosions, extraarticular disease,⬆️antiCCP,⬆️ESR & ⬆️DAS28(CRP), DAS28(ESR), CDAI & SDAI scores #EULAR2020 #eular20 https://t.co/OhI9NKpStE
      RT @uptoTate: SAPHO or PsA with CASPAR criteria? 1/3 of SAPHO pts meet PsA criteria (particularly active or hx of psoria

      Dr. Rachel Tate uptoTate

      4 years 6 months ago
      SAPHO or PsA with CASPAR criteria? 1/3 of SAPHO pts meet PsA criteria (particularly active or hx of psoriasis). Interestingly, most with osteitis did not meet CASPAR criteria while those with synovitis did. #EULAR2020 @RheumNow #AB0738 https://t.co/G4p6OiocE3
      RT @LeedsBRC: Congratulations from all of us at the BRC to Professor Paul Emery OBE for being awarded a Meritorious Awar

      NIHR Leeds BRC LeedsBRC

      4 years 6 months ago
      Congratulations from all of us at the BRC to Professor Paul Emery OBE for being awarded a Meritorious Award at EULAR 2020 #EULAR2020goesvirtual #EULAR2020 #FightingRMDsTogether https://t.co/z9T4AZ5P0u
      RT @ARD_BMJ: Guselkumab improved axial symptoms, over 24 weeks in active PsA patients with radiographic sacroiliitis. Po

      ARD & RMD Open ARD_BMJ

      4 years 6 months ago
      Guselkumab improved axial symptoms, over 24 weeks in active PsA patients with radiographic sacroiliitis. Post-hoc analysis from Discover1&2 studies (Prof P Helliwell). #OP0054. #EULAR2020, >GF
      RT @drdavidliew: Can fatigue in RA vary by bDMARD used? IL-6 inhibitor treatment associated with attaining a low fatigue

      David Liew drdavidliew

      4 years 6 months ago
      Can fatigue in RA vary by bDMARD used? IL-6 inhibitor treatment associated with attaining a low fatigue state (RR 1.20 vs csDMARDs). Given IL-6 secretion with HPA axis activation leads to fatigue/poor sleep, maybe something in this? RABBIT database OP0020 #EULAR2020 @RheumNow https://t.co/wzFcqdUMMV
      RT @carmona_loreto: 17,500 people connected at moment at the largest e-Congress I could imagine #EULAR2020 #EULAR2020goe

      Loreto Carmona 🖖 carmona_loreto

      4 years 6 months ago
      17,500 people connected at moment at the largest e-Congress I could imagine #EULAR2020 #EULAR2020goesvirtual
      RT @drdavidliew: You've got at least two good reasons not to forget about cardiovascular risk in ankylosing spondylitis.

      David Liew drdavidliew

      4 years 6 months ago
      You've got at least two good reasons not to forget about cardiovascular risk in ankylosing spondylitis. Traditional and inflammatory: it's the double whammy. Mike Nurmohamed from @Reade_020 #EULAR2020 @RheumNow https://t.co/GLH7wzvrLN
      RT @philipcrobinson: Use Of TNFi Before, During And The 1stY after Pregnancy Among Women With RA: Most of the women with

      Dr Philip Robinson philipcrobinson

      4 years 6 months ago
      Use Of TNFi Before, During And The 1stY after Pregnancy Among Women With RA: Most of the women with RA were not treated with TNFi before or in pregnancy. Women w. RA that continue Rx with TNFi through pregnancy were using certilozumab and etanercept #EULAR2020 @RheumNow Abs0302 https://t.co/bWKrpx1hx7
      RT @drdavidliew: Increased cardiovascular risk in:
      - AS patients (adj HR 4.6 vs non-rheum controls)
      - longer disease dur

      David Liew drdavidliew

      4 years 6 months ago
      Increased cardiovascular risk in: - AS patients (adj HR 4.6 vs non-rheum controls) - longer disease duration of inflammatory rheum disease (7% per year) in a Spanish national multicentre project (CARMA) w 5y follow-up Martin Martinez OP0002 #EULAR2020 @RheumNow https://t.co/BffbfPfkj0
      ×